RAD51 and hematopoietic and lymphoid cell neoplasm: Moreover, an ongoing human phase I/II trial conducted in patients with advanced solid and hematologic cancers by using CYT-0851, a first-in-class small molecular inhibitor of RAD51-mediated DNA repair, showed that two of 10 evaluable patients had partial responses and additional two more patients experienced stable disease [55].